Table-III.
Variables | TACE+lenvatinib group (n=46) | TACE group (n=57) | Fisher | P |
---|---|---|---|---|
CR | 5 (10.87) | 2 (3.51) | ||
PR | 27 (58.69) | 21 (36.84) | ||
SD | 9 (19.57) | 24 (42.11) | ||
PD | 5 (10.87) | 10 (17.54) | ||
Total effective rate | 32 (69.57) | 23 (40.35) | 9.454 | <0.05 |
Variables | TACE+lenvatinib group (n=46) | TACE group (n=57) | Fisher | P |
---|---|---|---|---|
CR | 5 (10.87) | 2 (3.51) | ||
PR | 27 (58.69) | 21 (36.84) | ||
SD | 9 (19.57) | 24 (42.11) | ||
PD | 5 (10.87) | 10 (17.54) | ||
Total effective rate | 32 (69.57) | 23 (40.35) | 9.454 | <0.05 |